Evidence analysisOctober 19, 2026Health & Science
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Vizimpro (active substance: dacomitinib) is a medicine approved in the European Union for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor receptor (EGFR) gene. It is classified as a tyrosine kinase inhibitor (TKI) that blocks the activity of EGFR, a protein often overactive in certain lung cancer cells, promoting uncontrolled tumor growth.
Clinical studies, primarily a randomized trial involving 452 patients, demonstrated that Vizimpro provides a median progression-free survival of about 15 months compared to 9 months for patients treated with gefitinib, another EGFR-targeting TKI. This reflects approximately a 6-month increase before disease progression.
The medicine is administered orally, typically as a 45 mg tablet once daily, and dosage adjustments may be necessary based on tolerability and side effects. Common side effects include diarrhea, rash, mouth inflammation, nail disorders, dryness of skin, loss of appetite, conjunctivitis, weight and hair loss, and potential liver enzyme elevation. Serious adverse effects occur in some patients, notably interstitial lung disease and severe diarrhea.
Despite a higher incidence of side effects relative to gefitinib, regulatory authorities have concluded that the benefits of Vizimpro outweigh the risks when used under medical supervision and with confirmed EGFR mutation status.
What the source claims
The source, the European Medicines Agency (EMA), provides a detailed European Public Assessment Report (EPAR) for Vizimpro. It states that:
- Vizimpro is authorized in the EU since April 2019 based on favorable efficacy and acceptable safety profiles.
- The medicine should only be prescribed to patients whose tumors have confirmed EGFR mutations via appropriate molecular testing.
- Treatment should continue as long as the patient benefits without intolerable side effects; physicians may reduce dosing or stop treatment if adverse reactions arise.
- Ongoing pharmacovigilance ensures continued monitoring of real-world safety and effectiveness.
- Detailed guidelines, including summary of product characteristics and patient leaflets, provide healthcare professionals and patients with instructions and precautions to ensure safe use.
What may be missing from the usual framing
The report and authorization focus on key clinical trial results and regulatory assessments, but some contextual aspects commonly relevant to understanding new cancer medicines are less emphasized or absent, such as:
- Long-term overall survival benefit: While progression-free survival improved, the source does not provide clear data on overall survival impact, which is critical for patient outcome assessment.
- Quality of life considerations: The impact of side effects on patients’ day-to-day functioning and quality of life is not detailed in the summary; given the notable side-effect profile, this information is important.
- Comparative cost and accessibility: Economic factors, pricing, and access within different EU countries are not discussed, though they influence implementation and treatment equity.
- Resistance mechanisms and subsequent therapy options: Lung cancer treatment often involves sequential drug use; the report does not address resistance patterns emerging with Vizimpro or subsequent lines of therapy after progression.
- Patient diversity: The demographics and genetic background diversity of the studied population are not provided, limiting understanding of differential effectiveness across populations.
Competing evidence or uncertainty
Evidence from a single main clinical trial underpins Vizimpro’s approval, demonstrating superiority to gefitinib in progression-free survival. However, competing or additional evidence exists in the broader oncology field:
- Other EGFR inhibitors, including osimertinib, have shown differing efficacy and safety profiles, some with evidence suggesting longer overall survival and better central nervous system penetration.
- Comparative head-to-head studies between different TKIs remain limited, and indirect comparisons can be confounded by trial design differences.
- Uncertainty remains about the optimal first-line therapy for EGFR-mutant NSCLC, with the choice influenced by mutation type, resistance mutation status, patient factors, and side effect profiles.
- Real-world effectiveness may differ from clinical trial efficacy due to broader patient characteristics, co-morbidities, and adherence patterns.
Why it matters
Non-small cell lung cancer with EGFR mutations represents a significant clinical challenge due to its poor prognosis and characteristic resistance to some conventional chemotherapies. New targeted treatments like Vizimpro offer potential improvements in delaying disease progression and improving patient outcomes. The availability of multiple EGFR inhibitors creates options but also complexity in treatment decisions.
Understanding the balance of benefits and risks—especially given substantial side effects—is crucial for informed patient care. Close monitoring and genetic testing are essential to tailor therapy appropriately. Additionally, transparency about what is known and unknown aids patients, clinicians, and policymakers in making evidence-based choices about lung cancer treatment strategies and resource allocation.
What to verify next
- Independent clinical trial data and meta-analyses comparing dacomitinib (Vizimpro) with other EGFR inhibitors, especially focusing on overall survival and quality of life metrics.
- Post-marketing surveillance and real-world evidence reports assessing safety, adverse event incidence, and management outside trial settings.
- Updates on clinical guidelines that incorporate newer evidence or compare different targeted therapies in EGFR-mutant NSCLC.
- Economic evaluations and health technology assessments to understand cost-effectiveness and access considerations in different health systems.
- Molecular research on mechanisms of resistance to Vizimpro and subsequent treatment options following disease progression.
Readers are encouraged to consult the original EMA source documentation for full details and to review the latest medical literature and clinical guidelines for comprehensive and updated information.
Source & verification
Primary source: What's new · October 19, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…